11.14.24
Kimberly-Clark Corporation announced that Joseph Romanelli, president of Human Health International for Merck & Co., Inc., Rahway, NJ, ("MSD") has been elected to its board of directors, effective immediately. In connection with the election, Kimberly-Clark's board size will increase from 12 to 13 directors.
"Joe Romanelli is an outstanding addition to the Kimberly-Clark Board of Directors," says Mike Hsu, chairman and chief executive officer of Kimberly-Clark. "As we advance our Powering Care strategy, we will benefit from Joe's global leadership experience and his expertise in using leading-edge science to save and improve lives around the world."
Romanelli has served as president of Human Health International for MSD, a global healthcare company that develops and manufactures medicines, vaccines, biologic therapies, and animal health products, since 2022. In this role, he oversees MSD's 75-plus markets outside of the U.S. and leads a team of 14,000 colleagues. Prior to joining MSD, Mr. Romanelli served as the chief executive officer of JiXing Pharmaceuticals, a China-based biopharmaceutical company. Previously, he served in a variety of strategic and operational roles with increasing responsibility at MSD and Schering-Plough for 25 years.
"Joe Romanelli is an outstanding addition to the Kimberly-Clark Board of Directors," says Mike Hsu, chairman and chief executive officer of Kimberly-Clark. "As we advance our Powering Care strategy, we will benefit from Joe's global leadership experience and his expertise in using leading-edge science to save and improve lives around the world."
Romanelli has served as president of Human Health International for MSD, a global healthcare company that develops and manufactures medicines, vaccines, biologic therapies, and animal health products, since 2022. In this role, he oversees MSD's 75-plus markets outside of the U.S. and leads a team of 14,000 colleagues. Prior to joining MSD, Mr. Romanelli served as the chief executive officer of JiXing Pharmaceuticals, a China-based biopharmaceutical company. Previously, he served in a variety of strategic and operational roles with increasing responsibility at MSD and Schering-Plough for 25 years.